MSLE — Satellos Bioscience Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1421642 ·
Ontario, Canada
Last close
$9.79
Market Cap
$203.94M
52W High
$10.00
52W Low
$5.44
ADV30
65,102
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -10,043,000 | -9,768,000 | 75,226,000 | 18,697,000 | 4,563,000 |
| Dec 2025 | 0 | — | -7,647,000 | -7,303,000 | 31,889,000 | 9,804,000 | 4,105,000 |
| Sep 2025 | 0 | — | -5,966,000 | -5,821,000 | 37,503,000 | 19,304,000 | 3,503,000 |
| Jun 2025 | 0 | — | -6,367,000 | -5,608,000 | 41,117,000 | 38,217,000 | 2,770,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,596,000
Investing CF
$-9,417,000
Financing CF
$2,241,000
CapEx
$-3,441
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.92
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-81,970,000
Inventory
—
Receivables
$370,000
ST Investments
$17,906,000
EBIT TTM
$-26,459,000
Pretax Income TTM
$-24,701,000
Interest Exp TTM
$0
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -26,459,000 | -24,873,000 | 31,889,000 | 4,105,000 | — | -23,596,000 |
| Dec 2024 | 0 | -20,398,000 | -20,634,000 | 50,747,000 | 3,583,000 | — | -18,252,000 |
| Dec 2023 | 0 | -11,656,113 | -11,977,235 | 33,490,000 | 2,734,000 | — | -8,732,851 |
| Dec 2022 | 0 | -6,209,844 | -8,342,175 | 4,567,492 | 2,085,175 | — | -4,260,978 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.87
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMUX | IMMUNIC, INC. | $201.19M | $14.77 | — |
| NGEN | NERVGEN PHARMA CORP. | $200.06M | $1.88 | — |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $199.74M | $12.53 | — |
| ARCT | Arcturus Therapeutics Holdings Inc. | $198.11M | $6.97 | — |
| KRRO | Korro Bio, Inc. | $209.99M | $14.56 | — |
News headlines (Yahoo Finance, 1h cache)
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update
2026-07-10 19:02 · Yahoo
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
2026-07-08 13:34 · Yahoo
Satellos Says Interim Phase 2 Data Shows SAT-3247 Improves Muscle Measures in Adult DMD Patients
2026-07-08 12:29 · Yahoo
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
2026-07-08 10:30 · Yahoo
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
2026-06-29 11:00 · Yahoo
Satellos to Present Clinical Program Updates at ICNMD 2026
2026-06-25 11:00 · Yahoo
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
2026-06-17 21:00 · Yahoo
Satellos to Participate in Upcoming Investor Conferences
2026-05-27 11:00 · Yahoo
We're Not Very Worried About Satellos Bioscience's (TSE:MSCL) Cash Burn Rate
2026-05-18 13:36 · Yahoo
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
2026-05-15 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.